Some of Pharma's Biggest Brands Face a New Reality
(Status: Pending)
Big pharma faces new pricing pressures as Medicare adds 15 well-known drugs to its negotiation list, including Pfizer's Xeljanz and Novartis' Cosentyx. These drugs, used by 1.8 million Medicare beneficiaries, account for $27 billion in spending. While negotiated prices won't take effect until 2028, the move signals long-term pricing pressure on established drugs, impacting revenue for major companies like Pfizer, Novartis, and Eli Lilly.
GuruFocus·
